Skip to main content

Table 3 Adverse events of special interest for ramucirumab

From: A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

  All
(N = 83) (%)
No ascites
(N = 43) (%)
Small to moderate ascites
(N = 26) (%)
Massive ascites
(N = 14) (%)
P value*
All (%) ≥ Gr3(%) All (%) ≥ Gr3(%) All (%) ≥ Gr3(%) All (%) ≥ Gr3(%)
Hypertension 24 (29) 2 (2) 11 (26) 0 10 (38) 1 (4) 3 (21) 1 (7) 0.27
Bleeding or haemorrhage 19 (23) 2 (2) 9 (21) 2 (5) 6 (23) 0 4 (29) 0 0.39
Proteinuria 9 (11) 0 4 (9) 0 5 (19) 0 0 0 0.16**
Liver injury or failure 6 (7) 0 2 (5) 0 2 (8) 0 2 (14) 0 0.48**
Gastrointestinal haemorrhage 5 (6) 2 (2) 3 (7) 2 (5)a 1 (4) 0 1 (7) 0 0.39
Gastrointestinal perforation 1 (1) 1 (1) 0 0 1 (4) 1 (4) 0 0 0.33
Infusion-related reaction 0 0 0 0 1 (4) 0 0 0 0.33**
  1. *Comparison in grade 3 or more
  2. **Comparison in all grades
  3. aOne patient died due to peritoneal metastasis which infiltrated to small intestine